These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 28213368)

  • 1. Effects of dabigatran according to age in atrial fibrillation.
    Lauw MN; Eikelboom JW; Coppens M; Wallentin L; Yusuf S; Ezekowitz M; Oldgren J; Nakamya J; Wang J; Connolly SJ
    Heart; 2017 Jul; 103(13):1015-1023. PubMed ID: 28213368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
    Stam-Slob MC; Connolly SJ; van der Graaf Y; van der Leeuw J; Dorresteijn JAN; Eikelboom JW; Peters RJG; Alings M; Visseren FLJ
    Circulation; 2019 Jun; 139(25):2846-2856. PubMed ID: 31046423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).
    Reilly PA; Lehr T; Haertter S; Connolly SJ; Yusuf S; Eikelboom JW; Ezekowitz MD; Nehmiz G; Wang S; Wallentin L;
    J Am Coll Cardiol; 2014 Feb; 63(4):321-8. PubMed ID: 24076487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
    Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Kent AP; Pogue J; Spahr J; Clemens A; Noack H; Diener HC; Wallentin L; Yusuf S; Connolly SJ
    Europace; 2016 Jul; 18(7):973-8. PubMed ID: 26944733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study.
    Verdecchia P; Reboldi G; Angeli F; Mazzotta G; Lip GYH; Brueckmann M; Kleine E; Wallentin L; Ezekowitz MD; Yusuf S; Connolly SJ; Di Pasquale G
    Europace; 2018 Feb; 20(2):253-262. PubMed ID: 28520924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
    Eikelboom JW; Connolly SJ; Hart RG; Wallentin L; Reilly P; Oldgren J; Yang S; Yusuf S
    J Am Coll Cardiol; 2013 Sep; 62(10):900-8. PubMed ID: 23770182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial.
    Proietti M; Hijazi Z; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Lane DA; Oldgren J; Roldan V; Yusuf S; Wallentin L;
    J Intern Med; 2018 Mar; 283(3):282-292. PubMed ID: 29044861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
    Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalizing the decision of dabigatran versus warfarin in atrial fibrillation: A secondary analysis of the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial.
    Reinhardt SW; Desai NR; Tang Y; Jones PG; Ader J; Spertus JA
    PLoS One; 2021; 16(8):e0256338. PubMed ID: 34411158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran use in elderly patients with atrial fibrillation.
    Avgil-Tsadok M; Jackevicius CA; Essebag V; Eisenberg MJ; Rahme E; Behlouli H; Pilote L
    Thromb Haemost; 2016 Jan; 115(1):152-60. PubMed ID: 26354766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
    Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
    Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry.
    Beyer-Westendorf J; Ebertz F; Förster K; Gelbricht V; Michalski F; Köhler C; Werth S; Endig H; Pannach S; Tittl L; Sahin K; Daschkow K; Weiss N
    Thromb Haemost; 2015 Jun; 113(6):1247-57. PubMed ID: 25739533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Dans AL; Connolly SJ; Wallentin L; Yang S; Nakamya J; Brueckmann M; Ezekowitz M; Oldgren J; Eikelboom JW; Reilly PA; Yusuf S
    Circulation; 2013 Feb; 127(5):634-40. PubMed ID: 23271794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
    Ezekowitz MD; Nagarakanti R; Noack H; Brueckmann M; Litherland C; Jacobs M; Clemens A; Reilly PA; Connolly SJ; Yusuf S; Wallentin L
    Circulation; 2016 Aug; 134(8):589-98. PubMed ID: 27496855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.
    Graham DJ; Reichman ME; Wernecke M; Zhang R; Southworth MR; Levenson M; Sheu TC; Mott K; Goulding MR; Houstoun M; MaCurdy TE; Worrall C; Kelman JA
    Circulation; 2015 Jan; 131(2):157-64. PubMed ID: 25359164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ; Wallentin L; Ezekowitz MD; Eikelboom J; Oldgren J; Reilly PA; Brueckmann M; Pogue J; Alings M; Amerena JV; Avezum A; Baumgartner I; Budaj AJ; Chen JH; Dans AL; Darius H; Di Pasquale G; Ferreira J; Flaker GC; Flather MD; Franzosi MG; Golitsyn SP; Halon DA; Heidbuchel H; Hohnloser SH; Huber K; Jansky P; Kamensky G; Keltai M; Kim SS; Lau CP; Le Heuzey JY; Lewis BS; Liu L; Nanas J; Omar R; Pais P; Pedersen KE; Piegas LS; Raev D; Smith PJ; Talajic M; Tan RS; Tanomsup S; Toivonen L; Vinereanu D; Xavier D; Zhu J; Wang SQ; Duffy CO; Themeles E; Yusuf S
    Circulation; 2013 Jul; 128(3):237-43. PubMed ID: 23770747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.